Syntis Bio Inc. has announced its launch, with a focus on advancing a pipeline of oral therapies engineered for optimization in the small intestine and a portfolio of enzyme replacement therapies to treat orphan metabolic and broad digestive disorders.
Researchers from Alteogen Inc. and affiliated organizations presented preclinical characterization of a novel long-acting growth hormone receptor (GHR) antagonist, ALT-B5.
After the phase IIa failure at lowering intraocular pressure to a statistically significant degree with SBI-100, Skye Bioscience Inc. is dropping work with the ophthalmic emulsion, meant to treat primary open-angle glaucoma or ocular hypertension. Resources are turning to the firm’s metabolic program, which includes nimacimab, targeting the cannabinoid 1 receptor, due to start a phase II trial in obesity during the third quarter of this year.
An Eli Lilly & Co. patent describes new glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of diabetes type 2, hyperglycemia and obesity.
The U.S. FDA clamped a full clinical hold Biomea Fusion Inc.‘s phase I/II study of BMF-219 for treating type 1 diabetes and type 2 diabetes. The hold sank the stock on June 7 as the company looked to find answers so it could sit down with the agency to discuss next steps.
Ventyx Biosciences Inc. has released promising preclinical data for its CNS-penetrant NLRP3 inhibitor VTX-3232 in murine diet-induced obesity (DIO) models.
Researchers from Septerna Inc. presented the discovery and preclinical characterization of novel parathyroid hormone PTH1 receptor (PTH1R) agonists being developed as a new treatment option against hypoparathyroidism.
Relay Therapeutics Inc. has disclosed three new programs from its existing preclinical pipeline, including two novel programs from its genetic disease portfolio and a potentially first-in-class NRAS-selective inhibitor.
An expert in hepatitis delta virus said Vir Biotechnology Inc.’s phase II findings with the monoclonal antibody tobevibart and the small interfering ribonucleic acid elebsiran in chronic disease could lead to a “change [in] the entire care cascade and paradigm.” Shares of Vir (NASDAQ:VIR) ended June 5 at $12.66, up $2.08, or 19.7%, on the clinical news.
RSS
